BACKGROUND: Natural killer (NK) cells have antiviral and antitumor activity that could be harnessed for the treatment of infections and malignancies. To maintain cell viability and enhance antiviral and antitumor effects, NK cells are frequently treated with cytokines. Here they performed an extensive assessment of the effects of cytokines on the phenotype and function of human NK cells. METHODS: They used cytometry by time-of-flight (CyTOF) to evaluate NK cell repertoire changes after stimulation with interleukin (IL)-2, IL-15 or a combination of IL-12/IL-15/IL-18. To analyze the high dimensional CyTOF data, they used several statistical and visualization tools, including viSNE (Visualization of t-Distributed Stochastic Neighbor Embedding), Citrus (Cluster identification, characterization, and regression), correspondence analysis, and the Friedman-Rafsky test. RESULTS: All three treatments (IL-2, IL-15, and IL-12/IL-15/IL-18) increase expression of CD56 and CD69. The effects of treatment with IL-2 and IL-15 are nearly indistinguishable and characterized principally by increased expression of surface markers including CD56, NKp30, NKp44, and increased expression of functional markers, such as perforin, granzyme B, and MIP-1β. The combination of IL-12/IL-15/IL-18 induces a profound shift in the repertoire structure, decreasing expression of CD16, CD57, CD8, NKp30, NKp46, and NKG2D, and dramatically increasing expression of IFN-γ. CONCLUSIONS: CyTOF provides insights into the effects of cytokines on the phenotype and function of NK cells, which could inform future research efforts and approaches to NK cell immunotherapy. There are several analytical approaches to CyTOF data, and the appropriate method should be carefully selected based on which aspect of the dataset is being explored.
BACKGROUND: Natural killer (NK) cells have antiviral and antitumor activity that could be harnessed for the treatment of infections and malignancies. To maintain cell viability and enhance antiviral and antitumor effects, NK cells are frequently treated with cytokines. Here they performed an extensive assessment of the effects of cytokines on the phenotype and function of human NK cells. METHODS: They used cytometry by time-of-flight (CyTOF) to evaluate NK cell repertoire changes after stimulation with interleukin (IL)-2, IL-15 or a combination of IL-12/IL-15/IL-18. To analyze the high dimensional CyTOF data, they used several statistical and visualization tools, including viSNE (Visualization of t-Distributed Stochastic Neighbor Embedding), Citrus (Cluster identification, characterization, and regression), correspondence analysis, and the Friedman-Rafsky test. RESULTS: All three treatments (IL-2, IL-15, and IL-12/IL-15/IL-18) increase expression of CD56 and CD69. The effects of treatment with IL-2 and IL-15 are nearly indistinguishable and characterized principally by increased expression of surface markers including CD56, NKp30, NKp44, and increased expression of functional markers, such as perforin, granzyme B, and MIP-1β. The combination of IL-12/IL-15/IL-18 induces a profound shift in the repertoire structure, decreasing expression of CD16, CD57, CD8, NKp30, NKp46, and NKG2D, and dramatically increasing expression of IFN-γ. CONCLUSIONS: CyTOF provides insights into the effects of cytokines on the phenotype and function of NK cells, which could inform future research efforts and approaches to NK cell immunotherapy. There are several analytical approaches to CyTOF data, and the appropriate method should be carefully selected based on which aspect of the dataset is being explored.
Authors: Megan A Cooper; Julie M Elliott; Peter A Keyel; Liping Yang; Javier A Carrero; Wayne M Yokoyama Journal: Proc Natl Acad Sci U S A Date: 2009-01-30 Impact factor: 11.205
Authors: Rizwan Romee; Stephanie E Schneider; Jeffrey W Leong; Julie M Chase; Catherine R Keppel; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger Journal: Blood Date: 2012-09-14 Impact factor: 22.113
Authors: Silke Paust; Harvinder S Gill; Bao-Zhong Wang; Michael P Flynn; E Ashley Moseman; Balimkiz Senman; Marian Szczepanik; Amalio Telenti; Philip W Askenase; Richard W Compans; Ulrich H von Andrian Journal: Nat Immunol Date: 2010-10-24 Impact factor: 25.606
Authors: Peng Qiu; Erin F Simonds; Sean C Bendall; Kenneth D Gibbs; Robert V Bruggner; Michael D Linderman; Karen Sachs; Garry P Nolan; Sylvia K Plevritis Journal: Nat Biotechnol Date: 2011-10-02 Impact factor: 54.908
Authors: Martin R Goodier; Chiara Lusa; Sam Sherratt; Ana Rodriguez-Galan; Ron Behrens; Eleanor M Riley Journal: Front Immunol Date: 2016-09-26 Impact factor: 7.561
Authors: Aaron J Wilk; Nancy Lynn-Benner Weidenbacher; Rosemary Vergara; Ole A W Haabeth; Ronald Levy; Robert M Waymouth; Paul A Wender; Catherine A Blish Journal: Blood Adv Date: 2020-09-08
Authors: Lisa M Kronstad; Christof Seiler; Rosemary Vergara; Susan P Holmes; Catherine A Blish Journal: J Immunol Date: 2018-08-24 Impact factor: 5.422
Authors: Nancy Q Zhao; Anne-Maud Ferreira; Philip M Grant; Susan Holmes; Catherine A Blish Journal: Front Immunol Date: 2020-05-12 Impact factor: 7.561
Authors: Moriah J Castleman; Stephanie M Dillon; Tezha A Thompson; Mario L Santiago; Martin D McCarter; Edward Barker; Cara C Wilson Journal: J Immunol Date: 2021-06-11 Impact factor: 5.426
Authors: Thanmayi Ranganath; Laura J Simpson; Anne-Maud Ferreira; Christof Seiler; Elena Vendrame; Nancy Zhao; Jason D Fontenot; Susan Holmes; Catherine A Blish Journal: Front Immunol Date: 2020-04-24 Impact factor: 7.561